The COVID-19 pandemic created growth opportunities for pharmaceutical and medical device companies. During the pandemic, they brought new products to market more quickly through emergency use authorizations and eased enforcement policies.
But behind those opportunities lay some serious risks. New products that came to market during the pandemic now face heightened FDA scrutiny. The agency recalled more medical devices in 2021 than it did in the previous five years, and in just the first half of 2022 pharmaceutical units have already hit a five-year high.
Earlier this year, the FDA issued a guidance encouraging companies to be “recall-ready.” Join Matt Walker (Director of Business Development at Sedgwick brand protection), as he shares key insights from pharmaceutical and medical device recall data over the past five years. During the session, Matt will also present best practices to help companies prepare themselves for handling product safety issues with advice on pre-planning (risk mitigation) and event management.